Clinical Trial Update: PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS [Phase 1]

View source ↗

Summary

Phase 1 trial update for PRGN-3006 adoptive cellular therapy targeting CD33-positive acute myeloid leukemia, including MRD-positive AML or higher-risk myelodysp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• PRGN-3006

Snippet

Sponsor: Precigen, Inc | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: ACTIVE_NOT_RECRUITING